Search Results

You are looking at 241 - 250 of 1,296 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Zhiyuan Zheng, Ahmedin Jemal, Reginald Tucker-Seeley, Matthew P. Banegas, Xuesong Han, Ashish Rai, Jingxuan Zhao, and K. Robin Yabroff

sample of the civilian noninstitutionalized US population. Because deidentified NHIS data are publicly available, this study was exempt from Institutional Review Board review. The survey collects information on demographic characteristics, access to and

Full access

Andrew G. Robinson, Xuejiao Wei, William J. Mackillop, Yingwei Peng, and Christopher M. Booth

( Figure 1 ). Table 1 shows the characteristics of these 8,005 patients; notably, only 39% (n=3,146) had previously received radical-intent surgery or radiation-therapy. The advanced age (75% were >70 years) and sex distribution (73% were male) were

Full access

Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos

Characteristics We used SEER data on patient age, year of diagnosis, race/ethnicity, marital status, poverty rate at the census tract, education level, practice setting, census tract rural-urban commuting area codes, geographic region, and tumor stage ( Table 1

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

measured. 15 Pathologic complete response (pathCR) was defined as the complete disappearance of all tumor cells. Results Patient Characteristics Of approximately 300 patients with rectal cancer treated between 2007 and 2012 at MSKCC and its

Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

characteristics are provided in Table 1 . Median patient age was 62 years (range, 25–97 years), and 466 patients were female (56%) and 369 were male (44%). Of this cohort, 370 (44%) were black, 305 (37%) were white, 84 (10%) were Hispanic, 22 (3%) were Asian, 10

Full access

Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa

liver. Figure 4 Timeline figure indicating the procedures and chemotherapy (cetuximab) in relation to total bilirubin. Table 1 Comparison of Treated Patients and Their Characteristics and Outcomes The successful

Full access

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

noncardia primaries. Demographic and clinical characteristics stratified by type of preoperative treatment are summarized in Table 1 . Among patients treated with preoperative chemotherapy, 43.8% of patients received adjuvant therapy (among whom 67

Full access

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover

validation cohorts. Model performance of the final bootstrapped model was assessed in the training and validation cohorts using receiver operating characteristic (ROC) curves with area under the curve (AUC) statistics; ROC curves compare sensitivity to

Full access

Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl

distribution of stage, year of diagnosis, and risk category in the treatment groups. Table 1. Patient Characteristics Some deviation from protocol-defined treatment was noted in the treatment groups ( supplemental eTable 1 ). In the chemo-PRT group, 3D

Full access

George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, and Dawn Provenzale

accredited by the American College of Surgeons Commission on Cancer in 2005; an additional 8 facilities [30%] were in the process of applying for accreditation). 21 Characteristics of the 27 facilities using CCQMS reports are detailed in Table 3